Oryx

ORYX identifies and develops highly innovative translational immunotherapy programs for indications with unmet medical needs. The company focuses on promising R&D projects from academia, advancing them through clinical proof-of-concept trials before moving on to further clinical development and commercial collaboration. All ORYX-selected programs, including oncolytic viruses and two therapeutic vaccines, are qualified for further clinical development and have successfully completed Phase I/IIa trials, demonstrating safety and efficacy. The ORYX management team, led by Dr. Bernard Huber, consists of a group of experts with extensive experience in translational medicine programs and drug development, supported by a top-tier scientific and clinical advisory board.